Literature DB >> 1977798

Unusual T cell populations in adult murine bone marrow. Prevalence of CD3+CD4-CD8- and alpha beta TCR+NK1.1+ cells.

M Sykes1.   

Abstract

The T cell populations present in normal murine bone marrow have not been previously analyzed in detail, mainly because of their relative rarity. In order to permit such analyses, bone marrow T cells were enriched by depleting Mac1-positive cells, which constitute 65 to 90% of bone marrow cells (BMC), and then studied by two-color flow cytometry. Analysis of the remaining cells revealed that the T cell profile of adult murine bone marrow is markedly different from that of other lymphoid organs. A very high proportion of bone marrow CD3+ cells (approximately one-third) are CD4-CD8-. CD3+CD4-CD8- cells are much more concentrated among BMC T cells than among thymocytes or splenic T cells, suggesting that bone marrow may be either a site of extrathymic TCR gene rearrangement, or a major site to which such cells home from the thymus. The expression of NK1.1 was also evaluated on Mac1-depleted BMC populations. Surprisingly, up to 39% of alpha beta TCR+ BMC were found to express NK1.1. Most alpha beta TCR+NK1.1+ BMC also expressed CD4 or CD8. NK1.1+ alpha beta TCR+ cells represented a much greater proportion of BMC T cells than of other lymphoid (splenocyte or thymocyte) T cell populations. Mac1-depleted BMC of nude mice contained very few cells with this phenotype. These results are consistent with the hypothesis that NK1.1+ alpha beta TCR+ cells are generated primarily in the thymus of normal animals and migrate preferentially to bone marrow, where they may function as regulatory elements in hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977798

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Natural killer 1.1(+) alpha beta T cells in the periimplantation uterus.

Authors:  Y Dang; J Beckers; C R Wang; K D Heyborne
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

2.  Requirement for natural killer T (NKT) cells in the induction of allograft tolerance.

Authors:  K I Seino; K Fukao; K Muramoto; K Yanagisawa; Y Takada; S Kakuta; Y Iwakura; L Van Kaer; K Takeda; T Nakayama; M Taniguchi; H Bashuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

3.  Lymphoid precursor cell lines have capacity to migrate to multiple lymphoid sites.

Authors:  H C O'Neill; K Ni; T J O'Neill
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 4.  Application of natural killer T-cells to posttransplantation immunotherapy.

Authors:  Shin-ichiro Fujii
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

5.  Development of Valpha4+ NK T cells in the early stages of embryogenesis.

Authors:  Y Makino; R Kanno; H Koseki; M Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

6.  The emergence of non-cytolytic NK1.1+ T cells in the long-term culture of murine tumour-infiltrating lymphocytes: a possible role of transforming growth factor-beta.

Authors:  K Tamada; M Harada; O Ito; M Takenoyama; T Mori; G Matsuzaki; K Nomoto
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

7.  A murine retrovirus induces proliferation of unique lymphoid cell lines expressing T-cell-receptor structures utilizing common variable region alpha and beta chain genes.

Authors:  H C O'Neill
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

8.  Germline transcription and expression of Tcrb-V8 genes in peripheral mouse lymphoid tissues.

Authors:  H C O'Neill; C J Jolly
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

Review 9.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

10.  Natural killer receptors: the burden of a name.

Authors:  Henrique Veiga-Fernandes; Dimitris Kioussis; Mark Coles
Journal:  J Exp Med       Date:  2010-02-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.